Survival of ovarian cancer in Iran: 2000-2004

Asian Pacific Journal of Cancer Prevention

Volumn 10, Issue 4, 2009, Pages 555-558

  Arab, Maliheh ^a   Khayamzadeh, Maryam ^a   Mohit, Mitra ^b   Hosseini, Maryam ^a   Anbiaee, Robab ^a   Tabatabaeefar, Morteza ^a   Ebrahimi, Mojgan ^c   Tehranian, Afseneh ^d   Akbari, Mohammad Esmaeil ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Azad University of MSHS   (Iran)

^c HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Age at diagnosis; Histology; Iran; Ovarian cancer; Survival

Indexed keywords

EID: 77951145108     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Akbari ME, Abachizadeh K, Khayamzadeh M, et al (2008) Iran cancer report. CRC, Shahid Beheshty University of Medical Sciences.
2. Australian Institute of Health and Welfare. Cancer in Australia 1998. Canberra: AHW.2001 .AHW cataloque .No: CAN12.
3. Averette HE. Hoskins W, Nguyen HN, et al (1993). National survey of ovarian carcinoma: 1. A patient care evaluation study of the American college of surgeons. Cancer, 71, 1629-38.
4. Baade P, Coory M, Ring I (2000). Cancer survival in Queensland 1982 to 1995. Brishane (QLD): Health information center, Queensland Health.
5. Balli S, Fey MF, Hanggi W, et al (2000). Ovarian cancer: an institutional review of patterns of care, health insurance and prognosis. Eur J Cancer, 36, 2061-68.
6. Berek JS. Berek & Novaks Gynecology. 14th ed. philadelphia. Berek JS. Hacker NF. Practical Gynecologic oncology.4th ed. Philadelphia. Lippincott Williams & wilkins.2005Lippincott Williams & Wilkins.2007.
7. Berg JW (1996). Morphologic classification of human cancer. In Schottenfeld D. Fraumeni JJ (eds). Cancer Epidemiology and Prevention. 2nd ed. New York, Oxford.
8. Bjorge T. Engeland A. Sundfor K. Trope CG (1998). Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian radium hospital. Acta Obstet Gynecol Scand, 77, 777-81.
9. Bray F, Loos AH, Tognazzo S, La Vecchia C (2005). Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries: 1953-2000. Int J Cancer, 113, 971-90.
10. Coutes M. Tracey E (2000). Cancer in New South Wales, incidence and mortality 1997. Sydney (NSW): NSW Cancer Council.
11. De Souza PL. Friedlander ML (1992). Prognostic factors in ovarian cancer. Hematol Oncol Clin N Am, 6, 761-82.
12. Disaia PJ. Creasman WT (2007). Clinical Gynecologic Oncology.7th ed. Mosby Elsevier.
13. Gata G, Lasota MB, Verdecchia A (1998). Survival of European women with gynecological tumors, during the period 1978-1989. Eur J Cancer, 34, 2218-25.
14. Guirk JT, Natarajan N (2005). Ovarian cancer incidence in the United States, 1992-1999. Gyn Oncol, 97, 519-23.
15. Hanai A (1990). Trends and differentials in ovarian cancer: incidence, mortality and survival experience. APMIS suppl, 12, 1-2.
16. Hannibal CG, Cortes R, Engholm G, Kjaer SK (2008). Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978-2002. Acta Obstet Gynecol Scand, 87, 1353-60.
17. Heintz APM, Odicino F,. Maisonneuve P, et al (2003). Carcinoma of the ovary. 25 th annual report on the results of treatment of gynecological cancer. Int J Gynecol Obstet, 83, 135-66.
18. Hoskins WJ, Perez CA, Young RC. Barakat RR. Markman M. Randall ME. Principles and practice of Gynecologic oncology.4th ed. Philadelphia: Lippincott Williams & wilkins.2005.
19. Islamic Republic of Iran, Ministry of Health and Medical Education (2005-2006). Iranian Annual of National cancer registration report. Health Deputy, Center for disease control & Prevention, Noncommunicable Deputy, cancer office.
20. Laurvick CL, Semmens JB, D Arcy C, Holman J (2003). Ovarian cancer in western Australia (1982-98): incidence, mortality and survival. Cancer, 27, 588-95.
21. Loka A, Tsukuma H, Ajiki W, Oshima A (2003). Ovarian cancer incidence and survival by histologic type in Osaka, Japan. Cancer Sci, 94, 292-6.
22. Makar AP. Baekelandt M. Trope CG. Kristensen GB (1995). The prognostic significance of residual disease, FIGO substage, tumor histology , and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol, 56, 175-80.
23. Markman M, Lewis JJ, Saigo P, et al (1993). Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. Cancer, 71, 634-7.
24. Markman M, Lewis JL, Saigo P, et al (1993). Impact of age on survival of patients with ovarian cancer. Gynecol Oncol, 49, 236-9.
25. McGuire V, Jesser CA, Whittemore AS (2002). Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol, 84, 399-403.
26. Mohagheghi MA, Mosavi-Jarrahi A, Malekzadeh R, Parkin M (2009). Cancer incidence in Tehran metropolis: The first report from the Tehran population-based cancer registry, 1998-2001. Arch Iran Med, 12, 15-23.
27. O'Malley CD, Cress RD, Campleman SL, Leiserowitz GS (2003). Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol, 91, 608-15.
28. Omura GA, Brady MF, Homesley HD, et al (1991). Long term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic oncology group experience. J Clin Oncol, 9, 1138-50.
29. Oriel KA, Hartenbach EM, Remington PL (1999). Trends in United States ovarian cancer mortality, 1979-1995. Obstet Gynecol, 93, 30-3.
30. Petterson F (1988). Annual report on the results of treatment in gynecological cancer. Vol 20. International federation of Gynecology and obstetrics. Stockholm. Panorama press AB. :110.
31. Quirk JT. Natarajan N (2005). Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol, 97, 519-23.
32. Ries LAG, Eisner MP, Kosary CI, et al (2001). SEER cancer statistics review, 1973-1998. Bethesda (MD): National Cancer Institute.
33. Rock JA. Jones HW. Telindes operative Gynecology. 10th ed. Philadelphia. Wolters Kluwer.2008.
34. Schiff M, Becker TM, Smith HO, Gilliland FD, Key CR (1996). Ovarian cancer incidence and mortality in American Indian, Hispanic, and Non-Hispanic white women in New Mexico. Cancer Epidemiol Biomarkers Prev, 5, 323-27.
35. Scholz HS, Benedicic C, Haas J, Tamussino K, Petru E (2001). stage IV ovarian cancer: prognostic factors and survival beyond 5 years. Anticancer Res, 21, 3729-32.
36. Scully RE (1999). Histological Classification of Ovarian Tumors. 2nd ed. Springer-Verlag, Berlin.
37. Sen U, Sankaranarayanan R, Mandal S, et al (2002). Cancer patterns in eastern India: The first report of the Kolkata cancer registry. Int J Cancer, 100, 86-91.
38. Skirnisdottir I, Garmo H, Wilander E, Holmberg L (2008). Borderline ovarian tumors in Sweden 1960-2005: Trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer, 123, 1897-901.
39. South Australian Cancer Registry (2000). Cancer report-Epidemiology of cancer in South Australia 1997-1999. Incidence, mortality and survival 1997 to 1999. Incidence and mortality (1999) analysed by type and geographical location.Twenty-three years of data-Adelaide (SA): South Australian cancer registry, Epidemiology Branch: 2000.
40. Thigpen T, Brady MF, Omura GA, et al (1993). Age as a prognostic factor in ovarian carcinoma. The Gynecology oncology group experience. Cancer, 71, 606-14.
41. Tsukuma H, Ajiki W, Ioka A, Oshima A; Research Group of Population-Based cancer registries of Japan (2006). Survival of cancer patients diagnosed between 1993 and 1996: a collaborative study of population-based cancer registries in Japan. Jpn J Clin Oncol, 36, 602-7.
42. Van Houwelingen JC, Ten Bokkel Huinink WW, Van der Burg ATM, Van Oosterom AT, Neijt JP (1989). Predictability of the survival of patients with ovarian cancer. J Clin Oncol, 769-73.
43. Vergote IB, Kaern J, Abeler VM (1993). Analysis of prognostic factors in stage 1 epithelial ovarian carcinoma : importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol, 169, 40-52.
44. Voest EE, Van Houwelingen JC, Neijt JP (1989). A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival measured with log(relative risk) as main objectives. Eur J Cancer Clin Oncol, 25, 711-20.